Determining kidney function-specific thresholds for N-terminal pro-B-type natriuretic peptide in heart failure risk prediction among patients with chronic kidney disease: a multicentre, observational, cohort study

What Was Tested

This observational study looks at BNP (Nesiritide).

Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels are common in patients with chronic kidney disease (CKD), but uniform thresholds derived from the general population may not accurately predict heart failure (HF) risk across stages of kidney function.

Who Took Part

According to the abstract, 18,261 patients were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

This retrospective cohort study used data from the China Renal Data System, including 18 261 patients with CKD without prior HF.

What Was Measured

Elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels are common in patients with chronic kidney disease (CKD), but uniform thresholds derived from the general population may not accurately predict heart failure (HF) risk across stages of kidney function.

Topics PubMed links to this paper include Biomarkers, China, Glomerular Filtration Rate, Heart Failure, Kidney, Natriuretic Peptide, Brain and Peptide Fragments.

The authors tagged it with the keywords Cohort Studies and Risk Assessment.

What This Means in Plain Language

This is an observational study of BNP (Nesiritide) in 18,261 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Heart (British Cardiac Society)), a journal based in England.

More context: the BNP (Nesiritide) compound page, all human trials.